1149 patents
Page 5 of 58
Utility
Complement Component C1R Inhibitors for Treating a Neurological Disease, and Related Compositions, Systems and Methods of Using Same
12 Oct 23
The present invention relates to complement C1r subcomponent (C1R) inhibitors for use in treatment of neurological diseases.
Alexander MUNK, Helene M. GYLLING, Jesse Eric HANSON, Lukasz J. KIELPINSKI
Filed: 9 Nov 22
Utility
Anti-Notch2 Antibodies and Conjugates and Methods of Use
12 Oct 23
The invention provides anti-Notch2 antibodies and conjugates and methods of using the same.
Cornelia Helen Rinderknecht Eller, Adel Mahmoud ElSohly, Kirthana Ganeshan, Daniel George Lafkas, Jian Mehr-Dean Payandeh, Yan Wu, Kathryn Duffy Bewley, Cecilia Pui Chi Chiu, Hoangdung Dang Ho, Siao-Ping Tsai
Filed: 18 Jan 23
Utility
TREATMENT OF CANCER USING COMBINATION THERAPIES COMPRISING GDC-6036 and GDC-0077
12 Oct 23
Provided herein are combination therapies comprising a KRasG12C inhibitor (e.g.
Mark Andrew MERCHANT, Jennifer Lee SCHUTZMAN, Zhen SHI, Chunyan SONG, Neekesh Vijay DHARIA, Stephanie Royer JOO
Filed: 4 Apr 23
Utility
Multimodal Prediction of Geographic Atrophy Growth Rate
12 Oct 23
A method and system for evaluating geographic atrophy in a retina.
Qi YANG, Neha Sutheekshna ANEGONDI, Simon Shang GAO
Filed: 2 Jun 23
Utility
Combination therapies
10 Oct 23
The present invention relates generally to the fields of molecular biology and growth factor regulation.
Gordon Bray, Iris Chan
Filed: 9 Aug 21
Utility
Solid forms of 3-((1R,3R)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azetidin-3- yl)amino)phenyl)-3-methyl-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol and processes for preparing fused tricyclic compounds comprising a substituted phenyl or pyridinyl moiety, including methods of their use
10 Oct 23
Provided herein are solid forms, salts, and formulations of 3-((1R,3R)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azetidin-3-yl)amino)phenyl)-3-methyl-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol, processes and synthesis thereof, and methods of their use in the treatment of cancer.
Cheol Keun Chung, Jie Xu, Hans Iding, Kyle Clagg, Michael Dalziel, Alec Fettes, Francis Gosselin, Ngiap-Kie Lim, Andrew McClory, Haiming Zhang, Paroma Chakravarty, Karthik Nagapudi, Sarah Robinson
Filed: 3 Dec 20
Utility
Combination Therapies for Treatment of HER2 Cancer
5 Oct 23
Provided are combination therapies comprising inavolisib (a.k.a.
Jennifer Lee Schutzman, Chunyan Song, Kyung Wha Song, Eirini Thanopoulou, Simon Peter Warburton, Anwesha Dey, Stephanie Royer Joo
Filed: 9 Jun 23
Utility
Prefilled Syringe and Method of Preparing a Prefilled Syringe
5 Oct 23
A method of preparing a prefilled syringe (1), comprises (i) obtaining a syringe barrel (11) having an open end (111) and a tip (112) with an orifice (113) essentially opposite to the open end (111), and a needle adaptor cap (12) assembled on the tip (112) of the syringe barrel, wherein the needle adaptor cap (12) has a rubber element (121) tightly sealing the orifice (113) of the tip (112) of the syringe barrel (11) and the syringe barrel (11) together with the needle adaptor cap (12) assembled on the tip (112) of the syringe barrel (11) is sterilized by a first sterilizing comprising a main step of exposing the syringe barrel (11) together with the needle adaptor cap (12) assembled on the tip (112) of the syringe barrel (11) to ethylene oxide for about 5 hours to about 60 hours at a relative humidity of about 40% to about 100% and at a temperature of about 30° C. to about 60° C.; (ii) filling a drug substance (14) through the open end (111) of the syringe barrel (11) into an interior of the syringe barrel; (iii) sealing the interior of the syringe barrel (11) by advancing a rubber stopper (13) through the open end (111) of the syringe barrel (11); (iv) packaging the syringe barrel (11) together with the rubber stopper (13) sealing the interior of the syringe barrel (11) and the needle adaptor cap (12) assembled on the tip (112) of the syringe barrel (11); and (v) second external surface sterilizing the packaged syringe barrel (11) together with the rubber stopper (13) sealing the interior of the syringe barrel (11) and the needle adaptor cap (12) assembled on the tip (112) of the syringe barrel (11).
Markus HEMMINGER, Ulla GRAUSCHOPF, Frank BAMBERG, Mayumi BOWEN, Robert MÜLLER, Flora FELSOVALYI, Denny CHRISTENSEN
Filed: 6 Jun 23
Utility
Process for the Preparation of Biheteroaryl Compounds and Crystal Forms Thereof
5 Oct 23
Processes for preparing biheteroaryl compounds are provided, including the biheteroaryl compound 3-(difluoromethoxy)-5-[2-(3,3-difluoropyrrolidin-1-yl)-6-[(1S,4S)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl]pyrimidin-4-yl]pyridin-2-amine.
Fabienne HOFFMANN-EMERY, Manuel KONRATH, Christian LAUTZ, Katrin Monika NIEDERMANN, Jonathan Ugo ORCEL, Diane Elizabeth CARRERA
Filed: 31 Mar 23
Utility
Automated Screening for Diabetic Retinopathy Severity Using Color Fundus Image Data
5 Oct 23
Methods and systems for evaluating diabetic retinopathy (DR) severity are provided herein.
Qi YANG, Fethallah BENMANSOUR, Daniela Ferrara CAVALCANTI, Dimitrios DAMOPOULOS
Filed: 2 Jun 23
Utility
Complement Component 4 Inhibitors for Treating Neurological Diseases, and Related Compositons, Systems and Methods of Using Same
5 Oct 23
The present invention relates to complement component 4 (C4) inhibitors for use in treatment of a neurological disease.
Alexander MUNK, Helene M. GYLLING, Jesse Eric HANSON, Lukasz J. KIELPINSKI
Filed: 9 Nov 22
Utility
Methods and Compositions for Non-small Cell Lung Cancer Immunotherapy
5 Oct 23
The disclosure provides methods and compositions for treating non-small cell lung cancer (NSCLC; e.g., squamous or non-squamous NSCLC, including stage IV NSCLC) in a subject, for example, by administering a treatment regimen that includes a PD-1 axis binding antagonist (e.g., atezolizumab) in combination with a platinum-based chemotherapy (e.g., cisplatin or carboplatin and gemcitabine) to the subject.
Mark Lawrence MCCLELAND, Simonetta MOCCI, Wei ZOU, Yu DENG, Hiroshi KURIKI
Filed: 27 Oct 22
Utility
Methods for Determining the Relative Distribution of Glucuronidation, Iduronidation, and Galacturonidation of Polypeptides
5 Oct 23
The present disclosure relates to methods and compositions for determining the relative distribution of glucuronidation, iduronidation, and/or galacturonidation of polypeptides, including stereoselective liquid chromatography-mass spectrometry (LC-MS) methods capable of achieving the simultaneous separation and relative quantitation of glucuronidation, iduronidation, and/or galacturonidation of polypeptides.
Yi Yang
Filed: 7 Jun 23
Utility
Assays for Fixed Dose Combinations
5 Oct 23
Assays to analyze quality and quantity attributes of fixed dose combinations are provided.
Cécile AVENAL, Nadine HOLZMANN, Michael NOAK, Tania RUCHTY, Gabriele Maria SCHAEFER, Franziska ZAEHRINGER
Filed: 11 Jan 23
Utility
Machine Learning Prediction of Injection Frequency In Patients with Macular Edema
5 Oct 23
A method and system for managing a treatment of a subject diagnosed with a macular edema condition.
Yvonna Yun LI, Verena Lisa STEFFEN, Fethallah BENMANSOUR, Michel James FRIESENHAHN, Zdenka HASKOVA
Filed: 22 Mar 23
Utility
Syringe and method of preparing syringe
3 Oct 23
A syringe (18) has a longitudinal body (28) with an interior (228) in which a pharmaceutical substance is arranged, a needle connected to one longitudinal end of the body (228) and a rigid needle shield (38) encasing the needle.
Frank Bamberg, Heather L. Flores, Robert Müller, Elisabeth Schaible, Edward Schwarb, Lionel Vedrine, Kewei Yang, Mathieu Rigollet, Pierre Goldbach, Baboo Dushyantsingh Goordyal, Ivy Lin, Florian Wildenhahn
Filed: 18 Feb 22
Utility
Anti-Notch2 Antibodies and Methods of Use
28 Sep 23
The invention provides anti-Notch2 antibodies and methods of using the same.
Cecilia Pui Chi Chiu, Yan Wu, Adel Mahmoud ElSohly, Daniel George Lafkas, Jian Mehr-Dean Payandeh, Hoangdung Dang Ho, Siao-Ping Tsai
Filed: 16 Jul 21
Utility
Continuous Integration and Development of Code In a Secure Environment
28 Sep 23
The present disclosure relates to techniques for continuous integration and continuous deployment of source code on a digital health platform.
Niaz Ahsan Jalal, Abdesslem Dridi
Filed: 24 Apr 23
Utility
Rolling Apparatus for Advancing Liquid Through Tubing
28 Sep 23
Provided herein is a tube rolling apparatus.
Thomas Eisele, Pasquale CATALDO, Scott WIESER, Warren Dana AWEAU, Ruel G. GATDULA, Nicholas RUMMEL, Arthi NARAYANAN, Dennis FRANKMANN, Orhan CELIK, Mirko MARINGER, Murat COSKUN, Stephen Christopher SLONE, Henzel DALMACIO, Dominik MARKS, Edward CHAN, Dustin Daniel Scott, Michael Asal
Filed: 28 Jul 21
Utility
Automated Screening for Diabetic Retinopathy Severity Using Color Fundus Image Data
28 Sep 23
Methods and systems for evaluating diabetic retinopathy (DR) severity are provided herein.
Fethallah BENMANSOUR, Daniela Ferrara CAVALCANTI
Filed: 2 Jun 23